Drug resistant TB - latest developments in epidemiology, diagnostics and management

Area of Science:

• Public Health
• Infectious Diseases
• Microbiology

Background:

• Drug-resistant Tuberculosis (DR-TB) poses a significant global health threat, characterized by increased morbidity, mortality, and treatment complexity.
• The World Health Organization categorizes DR-TB into five types, including Rifampicin-resistant TB (RR-TB), Multidrug-resistant TB (MDR-TB), pre-Extensively Drug-Resistant TB (pre-XDR-TB), and Extensively Drug-Resistant TB (XDR-TB).
• In 2020, an estimated 500,000 new RR-TB cases occurred, with only 157,903 notified, indicating a substantial gap in detection and treatment.

Approach:

• Rapid diagnostic methods such as GeneXpert, whole genome sequencing, and Myc-TB are emerging as crucial tools for timely resistance detection.
• Newer TB drugs and shorter treatment regimens have been developed and recommended for effective DR-TB management.
• This review synthesizes recent advancements in DR-TB epidemiology, diagnostics, and treatment strategies.

Key Points:

• Despite diagnostic and therapeutic progress, a significant proportion of DR-TB cases (two-thirds) remain undetected and untreated annually.
• Effective control and elimination of Tuberculosis hinge on prompt case detection, accurate diagnosis, and timely initiation of treatment.
• Addressing the gap in case finding is critical for mitigating the impact of DR-TB globally.

Conclusions:

• Continued innovation in diagnostics and therapeutics is essential for combating DR-TB.
• Enhanced surveillance and public health interventions are necessary to improve case detection rates.
• Global collaboration and resource allocation are vital for TB elimination efforts.